S
Siddappa N. Byrareddy
Researcher at University of Nebraska Medical Center
Publications - 152
Citations - 7188
Siddappa N. Byrareddy is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 22, co-authored 121 publications receiving 4599 citations. Previous affiliations of Siddappa N. Byrareddy include Emory University & Harvard University.
Papers
More filters
Journal ArticleDOI
Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).
Omalla A. Olwenyi,Shetty Ravi Dyavar,Arpan Acharya,Anthony T. Podany,Courtney V. Fletcher,Caroline L. Ng,St Patrick Reid,Siddappa N. Byrareddy +7 more
TL;DR: How changes in the SARS-CoV-2 genome and its structural architecture affect viral replication, immune evasion, and transmission within different human populations is reviewed.
Journal ArticleDOI
The Role of Integrin α4β7 in HIV Pathogenesis and Treatment.
James Arthos,Claudia Cicala,Fatima Nawaz,Siddappa N. Byrareddy,Francois Villinger,Philip J. Santangelo,Aftab A. Ansari,Anthony S. Fauci +7 more
TL;DR: Targeting α4β7 represents a novel therapeutic approach to prevent and treat HIV infection and describes the current knowledge and the gaps in understanding of the role of α4 β7 in HIV pathogenesis and treatment.
Journal ArticleDOI
SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
Journal ArticleDOI
Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions.
Mai Mohamed Abdelmoaty,Pravin Yeapuri,Jatin Machhi,Katherine E. Olson,Farah Shahjin,Vikas Kumar,You Zhou,Jingjing Liang,Kabita Pandey,Arpan Acharya,Siddappa N. Byrareddy,R. Lee Mosley,Howard E. Gendelman +12 more
TL;DR: In this paper, the authors investigated transcriptomic and proteomic profiles of human monocyte-derived macrophages and concluded that the SARS-CoV-2-infected host mounts a robust innate immune response characterized by a pro-inflammatory storm heralding end-organ tissue damage.
Journal ArticleDOI
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs.
Ujjwal Neogi,Kyle J. Hill,Anoop T. Ambikan,Xiao Heng,Thomas P. Quinn,Siddappa N. Byrareddy,Anders Sönnerborg,Stefan G. Sarafianos,Kamalendra Singh +8 more
TL;DR: Using computational and bioinformatics tools, this work presents the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its mainRNA polymerase, suggesting that investigational and approved nucleoside RNA polymerases inhibitors have potential asAnti-SARS- CoV- 2 drugs.